INmune Bio (INMB) Proxy Filing summary

Executive summary

• Special Meeting scheduled for November 18, 2025, to be held virtually for all shareholders.

• Main agenda: approval of repricing certain outstanding stock options and potential adjournment if more votes are needed.

• Record date for voting is September 30, 2025, with 26,585,258 shares outstanding.

• Board recommends voting in favor of both proposals.

Voting matters and shareholder proposals

• Proposal 1: Repricing of underwater stock options granted under the 2017, 2019, and 2021 Stock Incentive Plans to the closing price on the meeting date.

• Proposal 2: Adjournment of the meeting if more time is needed to solicit votes for Proposal 1.

• Each share gets one vote per proposal; no cumulative voting.

• Abstentions and broker non-votes have no effect if quorum is present.

• Shareholder proposals for the 2026 annual meeting must be submitted by February 27, 2026.

Board of directors and corporate governance

• Board is soliciting proxies and will bear all solicitation costs.

• David Moss appointed CEO and director effective August 13, 2025; Cory Ellspermann appointed Interim CFO effective August 4, 2025.

• Board recommends voting for both proposals and will vote proxies accordingly unless otherwise directed.